| | | | | | | | | | |
|
| |
|
| Dockets Entered
On August 17, 2005
Table of Contents
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1981N-0033P
|
| Antigingivitis & Antiplaque-Related Claims
|
|
|
|
|
| 2000N-0504
|
| Egg Safety Action Plan
|
|
|
|
|
| 2001P-0075
|
| Switch Status of Emergency Contraceptives from Rx to OTC
|
|
|
|
|
| 2002P-0317
|
| Recall Aspartame as a Neurotoxic Drug
|
|
|
|
|
| 2003N-0076
|
| Food Labeling: Trans Fatty Acids in Nutrition Labeling; Consumer research to consider possible footnote statements
|
|
|
|
|
| 2004N-0454
|
| Dietary Supplements; Premarket Notification for New Dietary Ingredient Notifications; Public Meeting
|
|
|
|
|
| 2004N-0456
|
| Serving Sizes of Products that Can Reasonably be Consumed at One Eating Occasion; Updating of Reference Amounts Customarily Consumed; Approaches for Recommending Smaller Portion Sizes
|
|
|
|
|
|
|
|
|
| 2004P-0015
|
| Deny approval of any New Drug Application ( NDA ) for recombinant salmon calcitonin (rsCT ) nasal spray
|
|
|
|
|
| 2004P-0223
|
| Whole Grain Descriptive Claims
|
|
|
|
|
| 2004Q-0151
|
| Qualified Health Claim (QHC): soy protein and cancer
|
|
|
|
|
| 2005D-0062
|
| Draft Guidance FDAs Drug Watch for Emerging Drug Safety
|
|
|
|
|
| 2005D-0202
|
| Guidance for Industry on Bar Code Label Requirements; Questions and Answers
|
|
|
|
|
| 2005N-0279
|
| Food Labeling; Gluten-Free Labeling of Foods; Public Meeting
|
|
|
|
|
| 2005P-0076
|
| OxyContin and Paladone removal from market and label changes limiting indications to severe chronic pain
|
|
|
|
|
| 2005P-0116
|
| To take the following actions with regard to aqueous-based drugs for inhalation that has been compounded by pharmacy operations
|
|
|
|
|
| 2005P-0242
|
| ANDA for a sterile Vancomycin Hydrochloirde,USP bulk package in 100 gram dosage strength in plasti bags
|
|
|
|
|
| 2005P-0282
|
| Require Health Messages on Soft Drinks
|
|
| |
|
| 1981N-0033P
|
| Antigingivitis & Antiplaque-Related Claims
|
|
|
|
|
| C
27
|
| Colgate-Palmolive Company
|
| Vol #:
|
| 92
|
|
|
|
|
| 2000N-0504
|
| Egg Safety Action Plan
|
|
|
|
|
| EMC 1935
|
| C. Santos
|
| Vol #:
|
| 31
|
|
|
|
|
| 2001P-0075
|
| Switch Status of Emergency Contraceptives from Rx to OTC
|
|
|
|
|
| EMC 14488
|
| H. Klaus, MD
|
| Vol #:
|
| 342
|
|
| |
|
| 2002P-0317
|
| Recall Aspartame as a Neurotoxic Drug
|
|
|
|
|
| EMC 501
|
| Mission Possible International
|
| Vol #:
|
| 8
|
|
|
|
|
| 2003N-0076
|
| Food Labeling: Trans Fatty Acids in Nutrition Labeling; Consumer research to consider possible footnote statements
|
|
|
|
|
| EMC 901
|
| F. Putter
|
| Vol #:
|
| 11
|
|
|
|
|
| EMC 902
|
| M. Crnolatas
|
| Vol #:
|
| 11
|
|
|
|
|
| EMC 903
|
| Y. Yi
|
| Vol #:
|
| 11
|
|
|
|
|
| EMC 904
|
| No Signature
|
| Vol #:
|
| 11
|
|
|
|
|
| EMC 905
|
| D. Hines
|
| Vol #:
|
| 11
|
|
|
|
|
| EMC 906
|
| J. Thomas
|
| Vol #:
|
| 11
|
|
| | | | | | | | |
|
| |
|
| EMC 907
|
| G. Barros
|
| Vol #:
|
| 11
|
|
|
|
|
| 2004N-0454
|
| Dietary Supplements; Premarket Notification for New Dietary Ingredient Notifications; Public Meeting
|
|
|
|
|
| EMC 1166
|
| T. Reeder
|
| Vol #:
|
| 29
|
|
|
|
|
| EMC 1167
|
| M. Farbstein
|
| Vol #:
|
| 29
|
|
|
|
|
| 2004N-0456
|
| Serving Sizes of Products that Can Reasonably be Consumed at One Eating Occasion; Updating of Reference Amounts Customarily Consumed; Approaches for Recommending Smaller Portion Sizes
|
|
|
|
|
|
|
|
|
|
|
| EMC 790
|
| J. Miller
|
| Vol #:
|
| 9
|
|
|
|
|
| 2004P-0015
|
| Deny approval of any New Drug Application ( NDA ) for recombinant salmon calcitonin (rsCT ) nasal spray
|
|
|
|
|
| PDN
1
|
| HFD-001 to Buc & Beardsley
|
| Vol #:
|
| 1
|
|
| |
|
| 2004P-0223
|
| Whole Grain Descriptive Claims
|
|
|
|
|
| C
26
|
| Quaker Oats Company (Quaker)
|
| Vol #:
|
| 5
|
|
|
|
|
| 2004Q-0151
|
| Qualified Health Claim (QHC): soy protein and cancer
|
|
|
|
|
| EMC
348
|
| The Weston A. Price Foundation
|
| Vol #:
|
| 9
|
|
|
|
|
| 2005D-0062
|
| Draft Guidance FDAs Drug Watch for Emerging Drug Safety
|
|
|
|
|
| EMC
2
|
| Consumer Healthcare Products Association (CHPA)
|
| Vol #:
|
| 2
|
|
|
|
|
| EMC
3
|
| Pfizer, Inc.
|
| Vol #:
|
| 2
|
|
|
|
|
| EMC
4
|
| Biotechnology Industry Organization (BIO)
|
| Vol #:
|
| 2
|
|
|
|
|
| 2005D-0202
|
| Guidance for Industry on Bar Code Label Requirements; Questions and Answers
|
|
|
|
|
| C
5
|
| Roxane Laboratories, Inc.
|
| Vol #:
|
| 1
|
|
|
|
|
| 2005N-0279
|
| Food Labeling; Gluten-Free Labeling of Foods; Public Meeting
|
|
|
|
|
| C 6
|
| M. Hoffman
|
| Vol #:
|
| 1
|
|
|
|
|
| C 7
|
| E. Findley
|
| Vol #:
|
| 1
|
|
|
|
|
| C 8
|
| G. F. Cresswell, M.D.
|
| Vol #:
|
| 1
|
|
|
|
|
| C 9
|
| C. B. Cresswell
|
| Vol #:
|
| 1
|
|
|
|
|
| 2005P-0076
|
| OxyContin and Paladone removal from market and label changes limiting indications to severe chronic pain
|
|
|
|
|
| LET
1
|
| HFD-005 to Kirk Van Rooyan and Barbara Van Rooyan
|
| Vol #:
|
| 1
|
|
|
|
|
| 2005P-0116
|
| To take the following actions with regard to aqueous-based drugs for inhalation that has been compounded by pharmacy operations
|
|
|
|
|
| C
2
|
| International Academy of Compounding Pharmacists (IACP)
|
| Vol #:
|
| 2
|
|
|
|
|
| 2005P-0242
|
| ANDA for a sterile Vancomycin Hydrochloirde,USP bulk package in 100 gram dosage strength in plasti bags
|
|
|
|
|
| AMD
1
|
| Samson Medical Technologies, LLC
|
| Vol #:
|
| 1
|
|
